Areva to begin US trial of cancer-fighting isotopeJanuary 24, 2011 in Medicine & Health / Cancer
A subsidiary of the French nuclear giant Areva said Monday it had received US clearance to begin a clinical trial of an isotope that targets cancer cells.
"Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments," Areva Med said in a statement.
The phase one trial, which assesses safety, will begin in 2011 and take about two years. The treatment's primary target will be pancreatic cancer, a company spokesman said.
"This landmark FDA authorization is a very important step that could lead to a potential treatment for very aggressive and lethal cancers," said Jacques Besnainou, CEO of Areva North America.
Areva announced last year the construction of a facility to produce lead-212 in the Limousin region of France.
(c) 2011 AFP
"Areva to begin US trial of cancer-fighting isotope" January 24, 2011 http://phys.org/news/2011-01-areva-trial-cancer-fighting-isotope.html